JP2022535527A5 - - Google Patents
Info
- Publication number
- JP2022535527A5 JP2022535527A5 JP2021571613A JP2021571613A JP2022535527A5 JP 2022535527 A5 JP2022535527 A5 JP 2022535527A5 JP 2021571613 A JP2021571613 A JP 2021571613A JP 2021571613 A JP2021571613 A JP 2021571613A JP 2022535527 A5 JP2022535527 A5 JP 2022535527A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025129110A JP2025172753A (ja) | 2019-06-04 | 2025-08-01 | 自己免疫疾患を治療するための方法および組成物 |
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962857232P | 2019-06-04 | 2019-06-04 | |
| US62/857,232 | 2019-06-04 | ||
| US201962863141P | 2019-06-18 | 2019-06-18 | |
| US62/863,141 | 2019-06-18 | ||
| US201962882310P | 2019-08-02 | 2019-08-02 | |
| US62/882,310 | 2019-08-02 | ||
| US201962933279P | 2019-11-08 | 2019-11-08 | |
| US62/933,279 | 2019-11-08 | ||
| US201962944988P | 2019-12-06 | 2019-12-06 | |
| US62/944,988 | 2019-12-06 | ||
| US202062968870P | 2020-01-31 | 2020-01-31 | |
| US62/968,870 | 2020-01-31 | ||
| US202063030860P | 2020-05-27 | 2020-05-27 | |
| US63/030,860 | 2020-05-27 | ||
| PCT/US2020/036177 WO2020247670A1 (en) | 2019-06-04 | 2020-06-04 | Methods and compositions for treating autoimmune diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025129110A Division JP2025172753A (ja) | 2019-06-04 | 2025-08-01 | 自己免疫疾患を治療するための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022535527A JP2022535527A (ja) | 2022-08-09 |
| JP2022535527A5 true JP2022535527A5 (https=) | 2023-06-23 |
| JPWO2020247670A5 JPWO2020247670A5 (https=) | 2023-06-23 |
Family
ID=73652045
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571613A Pending JP2022535527A (ja) | 2019-06-04 | 2020-06-04 | 自己免疫疾患を治療するための方法および組成物 |
| JP2025129110A Pending JP2025172753A (ja) | 2019-06-04 | 2025-08-01 | 自己免疫疾患を治療するための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025129110A Pending JP2025172753A (ja) | 2019-06-04 | 2025-08-01 | 自己免疫疾患を治療するための方法および組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12403200B2 (https=) |
| EP (1) | EP3980066A4 (https=) |
| JP (2) | JP2022535527A (https=) |
| KR (1) | KR20220016922A (https=) |
| CN (2) | CN114173820B (https=) |
| AU (1) | AU2020289360A1 (https=) |
| BR (1) | BR112021024328A2 (https=) |
| CA (1) | CA3140180A1 (https=) |
| IL (1) | IL288563A (https=) |
| MX (1) | MX2021014729A (https=) |
| SG (1) | SG11202113331QA (https=) |
| WO (1) | WO2020247670A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022512781A (ja) * | 2018-10-30 | 2022-02-07 | マジェンタ セラピューティクス インコーポレイテッド | 同種造血幹細胞移植の方法 |
| WO2022140388A1 (en) * | 2020-12-21 | 2022-06-30 | Allogene Therapeutics, Inc. | Protease-activating cd45-gate car |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002351204B2 (en) * | 2001-12-03 | 2008-07-10 | Abgenix, Inc. | Anti-CD45RB antibodies for use in treating autoimmune disease and transplant rejection |
| CN102365021B (zh) * | 2009-02-05 | 2015-07-15 | 伊缪诺金公司 | 新型苯并二氮杂*衍生物 |
| CN105246894A (zh) * | 2012-12-21 | 2016-01-13 | 斯皮罗根有限公司 | 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 |
| EP3174902B1 (en) * | 2014-08-01 | 2019-04-17 | Institut National de la Sante et de la Recherche Medicale (INSERM) | An anti-cd45rc antibody for use as drug |
| JP6863900B2 (ja) * | 2015-03-09 | 2021-04-21 | ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規アマトキシン−抗体コンジュゲート |
| HK1249534A1 (zh) * | 2015-04-06 | 2018-11-02 | 哈佛大学校长及研究员协会 | 用於非清髓性预处理的组合物和方法 |
| EP3222292A1 (en) * | 2016-03-03 | 2017-09-27 | Heidelberg Pharma GmbH | Amanitin conjugates |
| CN109641051A (zh) * | 2016-06-17 | 2019-04-16 | 美真达治疗公司 | 用于耗尽细胞的组合物和方法 |
| CA3045592A1 (en) * | 2016-12-21 | 2018-06-28 | Novartis Ag | Antibody drug conjugates for ablating hematopoietic stem cells |
| CA3079897A1 (en) * | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd117+ cells |
-
2020
- 2020-06-04 JP JP2021571613A patent/JP2022535527A/ja active Pending
- 2020-06-04 MX MX2021014729A patent/MX2021014729A/es unknown
- 2020-06-04 SG SG11202113331QA patent/SG11202113331QA/en unknown
- 2020-06-04 WO PCT/US2020/036177 patent/WO2020247670A1/en not_active Ceased
- 2020-06-04 CN CN202080055620.9A patent/CN114173820B/zh active Active
- 2020-06-04 EP EP20819317.7A patent/EP3980066A4/en active Pending
- 2020-06-04 BR BR112021024328A patent/BR112021024328A2/pt not_active IP Right Cessation
- 2020-06-04 CN CN202511717645.1A patent/CN121796623A/zh active Pending
- 2020-06-04 CA CA3140180A patent/CA3140180A1/en active Pending
- 2020-06-04 AU AU2020289360A patent/AU2020289360A1/en active Pending
- 2020-06-04 KR KR1020217043420A patent/KR20220016922A/ko active Pending
-
2021
- 2021-11-30 IL IL288563A patent/IL288563A/en unknown
- 2021-12-03 US US17/457,583 patent/US12403200B2/en active Active
-
2025
- 2025-08-01 JP JP2025129110A patent/JP2025172753A/ja active Pending
- 2025-08-27 US US19/312,214 patent/US20260069706A1/en active Pending